LXEO Profile
Lexeo Therapeutics, Inc., a clinical-stage genetic medicine company, specializes in developing advanced gene therapies for hereditary and acquired diseases. The company’s core focus is on creating innovative treatments for a range of genetic disorders through its proprietary adeno-associated virus (AAV) vector platform. Lexeo’s lead product candidates include LX2006, an AAVrh10-based gene therapy designed to treat Friedreich's ataxia (FA) cardiomyopathy; LX2020, another AAVrh10-based therapy aimed at arrhythmogenic cardiomyopathy; and LX2021, a gene therapy targeting DSP cardiomyopathy. Additionally, LX2022 is in development to address hypertrophic cardiomyopathy (HCM) caused by mutations in the TNNI3 gene.
The company is also advancing several gene therapies for neurological conditions, including LX1001 and LX1020, both AAVrh10-based therapies targeting APOE4 homozygous genetic variants, and LX1004, which focuses on treating CLN2 Batten disease, a severe neurodegenerative disorder. These therapies are intended to address significant unmet medical needs by leveraging Lexeo’s expertise in genetic medicine to develop targeted, potentially transformative treatments.
Lexeo Therapeutics is committed to pushing the boundaries of genetic medicine with a robust pipeline of gene therapy candidates. Its approach involves using cutting-edge gene editing technologies and AAV vectors to correct or modify genetic mutations at the source, offering the potential for long-term therapeutic benefits. The company's research and development efforts are supported by a strong foundation in genetic science and a commitment to advancing novel treatments through clinical trials.
Founded in 2017 and headquartered in New York, Lexeo Therapeutics is at the forefront of genetic medicine innovation. The company continues to explore and expand its pipeline, aiming to bring new therapies to patients with genetic disorders and contribute to the advancement of precision medicine.
|
